| 1 |
35046573 | An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. | 2022 Mar |
1 |
| 2 |
35321335 | Omicron Variant of SARS-CoV-2 Virus: In Silico Evaluation of the Possible Impact on People Affected by Diabetes Mellitus. | 2022 |
2 |
| 3 |
35458513 | How Do Point Mutations Enhancing the Basic Character of the RBDs of SARS-CoV-2 Variants Affect Their Transmissibility and Infectivity Capacities? | 2022 Apr 10 |
4 |
| 4 |
32448098 | Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor. | 2021 Jul |
2 |
| 5 |
33583954 | Computational search for drug repurposing to identify potential inhibitors against SARS-COV-2 using Molecular Docking, QTAIM and IQA methods in viral Spike protein - Human ACE2 interface. | 2021 May 15 |
1 |
| 6 |
33657325 | An Active Site Inhibitor Induces Conformational Penalties for ACE2 Recognition by the Spike Protein of SARS-CoV-2. | 2021 Mar 18 |
1 |
| 7 |
33951227 | The role and significance of angiotensin-converting enzyme 2 peptides in the treatment of coronavirus disease 2019. | 2021 Jun |
1 |
| 8 |
33962629 | Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte. | 2021 May 7 |
1 |
| 9 |
34031383 | Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication. | 2021 May 24 |
1 |
| 10 |
33200028 | Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization. | 2020 |
1 |
| 11 |
33254553 | A role of glycation and methylation for SARS-CoV-2 infection in diabetes? | 2020 Nov |
1 |
| 12 |
24227843 | TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. | 2014 Jan |
2 |